{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:48:33Z","timestamp":1782211713135,"version":"3.54.5"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inhaled corticoids (ICS) made a dramatic breakthrough in the management of asthma in the late eighties resulting in a sharp reduction in morbidity and mortality in the following decades. Soon after, the association between ICS and long acting \u03b22 agonists (LABA) soon became the gold standard of maintenance asthma treatment. With the advent of sputum induction it has become clear that asthma could not be considered as a unique entity but rather a display of several inflammatory phenotypes. Eosinophilic phenotype shows good response to ICS while non-eosinophilic, and in particular the neutrophilic phenotype, seems to be more resistant. Severe asthmatics show insufficient asthma control despite ICS\/LABA. Those who are allergic and eosinophilic may benefit from add-on treatment with anti-IgE or anti-IL-5. Severe neutrophilic asthma could benefit from maintenance treatment with macrolides while thermoplasty offers some promise to those in whom airway smooth muscle hypertrophy contributes to disease instability<\/jats:p>","DOI":"10.1515\/jtim-2015-0014","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T05:22:28Z","timestamp":1480915348000},"page":"113-115","source":"Crossref","is-referenced-by-count":2,"title":["A historical perspective: Are inhaled corticoids sufficient to control asthma?"],"prefix":"10.1515","volume":"3","author":[{"given":"Renaud","family":"Louis","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, GIGA Inflammation, Immunity and Infection Research Group , CHU Liege , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Demarche","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, GIGA Inflammation, Immunity and Infection Research Group , CHU Liege , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, GIGA Inflammation, Immunity and Infection Research Group , CHU Liege , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2015,9,30]]},"reference":[{"key":"2026062310095804863_j_--_ref_001","doi-asserted-by":"crossref","unstructured":"Louis R, Schleich F, Barnes PJ. Corticosteroids: still at the frontline in asthma treatment? Clin Chest Med 2012;33:531-41.","DOI":"10.1016\/j.ccm.2012.05.004"},{"key":"2026062310095804863_j_--_ref_002","doi-asserted-by":"crossref","unstructured":"Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O\u2019Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.","DOI":"10.1056\/NEJM199711133372001"},{"key":"2026062310095804863_j_--_ref_003","doi-asserted-by":"crossref","unstructured":"Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-707.","DOI":"10.1056\/NEJMoa1010846"},{"key":"2026062310095804863_j_--_ref_004","doi-asserted-by":"crossref","unstructured":"Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013;1:23-31.","DOI":"10.1016\/S2213-2600(13)70012-2"},{"key":"2026062310095804863_j_--_ref_005","doi-asserted-by":"crossref","unstructured":"Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744-53.","DOI":"10.1016\/S0140-6736(06)69284-2"},{"key":"2026062310095804863_j_--_ref_006","doi-asserted-by":"crossref","unstructured":"Louis R, Joos G, Michils A, Vandenhoven G. A comparison of budesonide\/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract 2009;63:1479-88.","DOI":"10.1111\/j.1742-1241.2009.02185.x"},{"key":"2026062310095804863_j_--_ref_007","doi-asserted-by":"crossref","unstructured":"Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013;13:11.","DOI":"10.1186\/1471-2466-13-11"},{"key":"2026062310095804863_j_--_ref_008","doi-asserted-by":"crossref","unstructured":"Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma.Lancet 1999;353:2213-4.","DOI":"10.1016\/S0140-6736(99)01813-9"},{"key":"2026062310095804863_j_--_ref_009","doi-asserted-by":"crossref","unstructured":"Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9.","DOI":"10.1136\/thorax.57.10.875"},{"key":"2026062310095804863_j_--_ref_010","doi-asserted-by":"crossref","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73.","DOI":"10.1183\/09031936.00202013"},{"key":"2026062310095804863_j_--_ref_011","doi-asserted-by":"crossref","unstructured":"Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16.","DOI":"10.1111\/j.1398-9995.2004.00772.x"},{"key":"2026062310095804863_j_--_ref_012","doi-asserted-by":"crossref","unstructured":"Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al. \u201cReal-life\u201d effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009;103:1633-42.","DOI":"10.1016\/j.rmed.2009.06.014"},{"key":"2026062310095804863_j_--_ref_013","doi-asserted-by":"crossref","unstructured":"Louis R. Anti-IgE: a significant breakthrough in the treatment of airway allergic diseases. Allergy 2004;59:698-700.","DOI":"10.1111\/j.1398-9995.2004.00548.x"},{"key":"2026062310095804863_j_--_ref_014","doi-asserted-by":"crossref","unstructured":"Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014;108:1723-32.","DOI":"10.1016\/j.rmed.2014.10.007"},{"key":"2026062310095804863_j_--_ref_015","doi-asserted-by":"crossref","unstructured":"Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.","DOI":"10.1016\/S0140-6736(02)11679-5"},{"key":"2026062310095804863_j_--_ref_016","doi-asserted-by":"crossref","unstructured":"Bel EH, Ortega HG, Pavord ID. Glucocorticoids and mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:2434.","DOI":"10.1056\/NEJMc1412892"},{"key":"2026062310095804863_j_--_ref_017","doi-asserted-by":"crossref","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2026062310095804863_j_--_ref_018","doi-asserted-by":"crossref","unstructured":"Schleich FN, Chevremont A, Paulus V, Henket M, Manise M, Seidel L, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma.Eur Respir J 2014;44:97-108.","DOI":"10.1183\/09031936.00201813"},{"key":"2026062310095804863_j_--_ref_019","doi-asserted-by":"crossref","unstructured":"Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32.","DOI":"10.1164\/rccm.201103-0396OC"},{"key":"2026062310095804863_j_--_ref_020","doi-asserted-by":"crossref","unstructured":"Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187:804-11.","DOI":"10.1164\/rccm.201208-1414OC"},{"key":"2026062310095804863_j_--_ref_021","unstructured":"Schleich F, Louis R. [Targeted asthma therapies: confirmations, hopes, and disappointments]. Rev Med Liege 2012;67:14-21."},{"key":"2026062310095804863_j_--_ref_022","doi-asserted-by":"crossref","unstructured":"Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma.Am J Respir Crit Care Med 2008;177:148-55.","DOI":"10.1164\/rccm.200707-1134OC"},{"key":"2026062310095804863_j_--_ref_023","doi-asserted-by":"crossref","unstructured":"Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial.Thorax 2013;68:322-9.","DOI":"10.1136\/thoraxjnl-2012-202698"},{"key":"2026062310095804863_j_--_ref_024","doi-asserted-by":"crossref","unstructured":"Louis R, Djukanovic R. Is the neutrophil a worthy target in severe asthma and chronic obstructive pulmonary disease? Clin Exp Allergy 2006;36:563-7.","DOI":"10.1111\/j.1365-2222.2006.02493.x"},{"key":"2026062310095804863_j_--_ref_025","doi-asserted-by":"crossref","unstructured":"Dombret MC, Alagha K, Philippe BL, Yves BP, Joos G, Laviolette M, et al. Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults.Eur Respir Rev 2014;23:510-8.","DOI":"10.1183\/09059180.00005114"},{"key":"2026062310095804863_j_--_ref_026","doi-asserted-by":"crossref","unstructured":"Heinen V, Schleich F, Duysinx B, Kirsch M, Louis R. [Bronchial thermoplasty: a real advancement in the treatment of asthma].Rev Med Suisse 2014;10:1544,1546-4,1548.","DOI":"10.53738\/REVMED.2014.10.439.1544"},{"key":"2026062310095804863_j_--_ref_027","unstructured":"Louis R, Manise M, Sele J, Schleich F. [Inertia and adherence as factors influencing asthma control].Rev Med Liege 2010;65:338-42."}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/jtim\/3\/3\/article-p113.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2015-0014\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2015-0014\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:13:00Z","timestamp":1782209580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2015-0014\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,1]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,9,30]]},"published-print":{"date-parts":[[2015,9,1]]}},"alternative-id":["10.1515\/jtim-2015-0014"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2015-0014","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,1]]}}}